Education
About Us
Working with TipRanks
Follow Us
CapsoVision, Inc. (CV)
NASDAQ:CV
Top Page
CapsoVision, Inc.
(NASDAQ:CV)
Select Model
Select Model
Rating:52Neutral
Price Target:
$4.50
▲(0.90% Upside)
CapsoVision, Inc. has a low overall stock score primarily due to its poor financial performance, which is a significant concern. The technical analysis provides some positive momentum, but the lack of valuation data limits a comprehensive assessment. The absence of earnings call and corporate events data further constrains the evaluation.
CapsoVision, Inc. (CV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$217.27M
Dividend YieldN/A
Average Volume (3M)49.56K
Price to Earnings (P/E)―
Beta (1Y)1.97
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees90
SectorHealthcare
Sector Strength45
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,774,067
10 Day Avg. Volume27,189
30 Day Avg. Volume49,556
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.17Price Target Upside15.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
CapsoVision, Inc. Business Overview & Revenue Model
Company DescriptionMedical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics
How the Company Makes MoneyCapsoVision generates revenue primarily through the sale of its CapsoCam capsule endoscopy systems and related disposable products, such as the capsules used in procedures. The company also earns revenue from partnerships with healthcare providers and institutions, which may include training, support services, and bulk purchase agreements. Additionally, CapsoVision may explore collaborations with pharmaceutical companies for research and clinical trials, further diversifying its revenue streams. The company's business model is built on establishing a strong presence in hospitals and outpatient clinics, aiming to create long-term relationships that lead to repeat purchases and ongoing service contracts.
CapsoVision, Inc. Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
15
Very Negative
Cash Flow
20
Very Negative
| Breakdown | Dec 2024 | Dec 2023 |
|---|---|---|
Income Statement | ||
| Total Revenue | 11.76M | 9.75M |
| Gross Profit | 6.38M | 5.49M |
| EBITDA | -19.40M | -10.96M |
| Net Income | -19.90M | -11.30M |
Balance Sheet | ||
| Total Assets | 16.80M | 21.53M |
| Cash, Cash Equivalents and Short-Term Investments | 9.32M | 14.56M |
| Total Debt | 1.24M | 1.51M |
| Total Liabilities | 146.31M | 131.37M |
| Stockholders Equity | -129.51M | -109.84M |
Cash Flow | ||
| Free Cash Flow | -20.24M | -11.56M |
| Operating Cash Flow | -20.09M | -10.80M |
| Investing Cash Flow | -153.00K | -754.00K |
| Financing Cash Flow | 15.07M | 20.53M |
CapsoVision, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $39.92B | 33.02 | 19.88% | 0.73% | 4.48% | -11.52% | |
70 Outperform | $3.36B | 60.82 | 1.76% | ― | 0.76% | ― | |
61 Neutral | $458.97M | ― | -17.10% | ― | 2.73% | 87.03% | |
52 Neutral | $217.27M | ― | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $60.94M | ― | 84.03% | ― | -13.83% | 87.09% |
* Healthcare Sector Average
CV
CapsoVision, Inc.
4.46
0.06
1.36%
A
Agilent
136.62
-6.47
-4.52%
ANGO
AngioDynamics
11.00
4.55
70.54%
NVST
Envista Holdings
19.06
1.22
6.84%
NEUE
NeueHealth Inc
6.75
0.91
15.58%
PFSA
Profusa
0.33
-11.45
-97.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.